Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Investigators Implicate Well-known Protein in Fibrosis
Uncategorized

Investigators Implicate Well-known Protein in Fibrosis

By medwebNov 29, 2012
Share
Facebook Twitter Email
John Varga, MD, the John and Nancy Hughes Distinguished Professor of Rheumatology and professor of dermatology has co-authored a paper that reveals a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis.

An international multi-disciplinary research team led by Northwestern Medicine scientists has uncovered a new role for the protein toll-like receptor 4 (TLR4) in the development of tissue fibrosis, or scarring. 

This finding, recently reported in the American Journal of Pathology, has implications for the treatment of scleroderma, a condition for which there currently is no effective treatment. 

TLR4 was previously implicated in inflammation, but its role in tissue fibrosis was unknown. Fibrosis is a hallmark of scleroderma and contributes to a range of common diseases including pulmonary fibrosis, kidney fibrosis, liver cirrhosis, and radiation-induced scarring. 

“We found that when the gene for TLR4 was mutated in mice, the mice became resistant to experimental scleroderma,” said the study’s first author Swati Bhattacharyya, PhD, research assistant professor of rheumatology. “Moreover, scleroderma patients showed abnormal TLR4 levels in fibrotic skin and lung tissue. This tells us we have found a therapeutic target.” 

Scleroderma is a chronic autoimmune disease which causes progressive tightening of the skin and can lead to serious internal organ damage and, in some cases, death. Scleroderma affects an estimated 300,000 people in the U.S., most frequently young-to-middle-aged women. Its cause and pathogenesis are unknown. 

Swati Bhattacharyya, PhD, research assistant professor of rheumatology, is the first-author of new research that has implications for the treatment of scleroderma.

“The Northwestern research team continues to make fundamental discoveries that enhance our scientific understanding of scleroderma,” said co-author John Varga, MD, the John and Nancy Hughes Distinguished Professor of Rheumatology and professor of dermatology. “Careful dissection of the role of individual proteins in this disease enables us to make real progress toward novel treatments.” 

Researchers from Northwestern, Boston University, the University of Pittsburgh, and the University Medical Center Nijmegen, in the Netherlands contributed to the study, which relied on tissue samples from human scleroderma patients and mouse models.

Agents that block TLR4 are already being developed for inflammation and sepsis in humans. Effective TLR4 inhibitor drugs may blunt and even possibly reverse the fibrosis in scleroderma, says Bhattacharyya. However, earlier attempts to develop therapeutics that block TLR4 have met with failure due to toxicity. 

“These results, while significant, are preliminary. We now know that TLR4 plays a role in scleroderma, but much research remains to be done to develop safe and effective drugs to inhibit this pathway,” she says.

The investigators are currently studying additional mouse models to better understand the role of TLR4 in fibrosis and are developing novel small molecules to selectively block TLR4 as a potential therapy. 

This study was supported by grant AR-42309 from The National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

Research
Share. Facebook Twitter Email

Related Posts

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Novel Intracellular Signaling Mechanisms Promote Melanoma Growth

Sep 21, 2023

Comments are closed.

Latest News

Feinberg Investigators Identify How a Residential Neighborhood Can Impact Health

Sep 22, 2023

Robert Lamb, Renowned Expert on Influenza Virus, Dies at 72

Sep 22, 2023

Bethany Ekesa, Associate Director of SPARC, Honored with Jean E. Shedd University Citizenship Award

Sep 21, 2023

Combination Immunotherapy Shows No Additional Benefit for Most Advanced Cancers

Sep 21, 2023

Novel Intracellular Signaling Mechanisms Promote Melanoma Growth

Sep 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230914_NM461
20230914_NM644
20230914_NM345
20230914_NM444
20230914_NM464
20230914_NM520
20230914_NM673
20230914_NM641
20230914_NM612
20230914_NM608
20230914_NM602
20230914_NM597

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.